Competitor Analysis: Interleukin-23 & IL-12/23 Antagonists

Publisher: La Merie Publishing
Pages: 16
Format: PDF and Online
Product Line:
Competitor Analysis
Product Line:
Target Pipeline
Product Code: LMCA0150
Release Date: September of 2015

100.00 €
Free of 21 % VAT (except in Spain and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Competitor Analysis: Interleukin-23 & IL-12/23 Antagonists

The Competitive Intelligence report about Interleukin-23 (IL-23) and IL-12/23 antagonists provides a competitor analysis of approved or being developed novel antagonists of interleukin-23 and IL-12/23 (p40 subunit) for treatment of psoriasis and other inflammatory diseases as of September 2015. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report provides a compilation of active products and projects on the market or in research and development as specific IL-23 or IL-12/23 (p40) antagonists as well as dual target IL-23 antagonists for treatment of immunologic diseases. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes
  • Target / Mechanism of Action
  • Class of Compound
  • Company
  • Product Category
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.



Competitor Analysis: Interleukin-23 & IL-12/23 Antagonists

Table of Contents

  • IL-12/23 (p40) Antagonists
  • Selective IL-23 Antagonists
  • Dual Target IL-23 Antagonists
  • Corporate IL-23 & IL-12/23 R&D Portfolios


The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up